Navigating Diabetes Management During Cancer Treatment: Emerging Insights on GLP-1 Receptor Agonists
For individuals facing both diabetes and cancer, managing blood sugar levels becomes substantially more complex. Cancer treatments – chemotherapy, radiation, and hormone therapy - frequently enough disrupt the body’s delicate metabolic balance, creating unique challenges for effective diabetes care. This article explores these challenges and dives into recent research regarding a promising class of medications, GLP-1 receptor agonists, and their potential impact on cancer survival.
The Interplay between Cancer Treatment and Blood Sugar Control
Cancer and its treatment can profoundly affect blood glucose management. It’s a two-way street where cancer impacts diabetes, and diabetes can influence cancer treatment outcomes.
Here’s how common cancer therapies can disrupt blood sugar control:
Chemotherapy: Side effects like mouth sores, nausea, and appetite loss can lead to inconsistent eating patterns and hypoglycemia (low blood sugar).
Radiation Therapy: This treatment can trigger a temporary release of glucose, causing hyperglycemia (high blood sugar), and often leads to debilitating fatigue impacting meal schedules.
Hormone Therapy: Commonly used for breast and prostate cancers, hormone therapy can induce nausea and fatigue, hindering consistent nutrition and activity.
Steroids: Frequently used alongside chemotherapy to manage nausea, steroids are known to elevate blood sugar levels.
Despite these hurdles, maintaining stable blood sugar is critical during cancer treatment. Good glycemic control can reduce infection risk and perhaps improve overall treatment effectiveness. The CDC recommends focusing on a balanced diet when possible, prioritizing calorie and protein-rich, palatable foods.2
GLP-1s: A New Avenue for Consideration?
Recent research is exploring whether certain diabetes medications might offer benefits beyond blood sugar control, specifically in the context of cancer. GLP-1 receptor agonists (GLP-1s) are a class of drugs initially developed for type 2 diabetes (T2D) that have garnered attention for their potential anti-cancer properties.A retrospective study utilizing Medicare data (2013-2020) investigated the association between GLP-1s and all-cause mortality in older adults (66+) with both T2D and one of nine common cancers: thyroid, pancreatic, bladder, colorectal, lung, kidney, breast, endometrial, or prostate. 1
Study Design & Findings:
The study compared outcomes in patients prescribed GLP-1s versus two other diabetes medication classes:
GLP-1s vs.SGLT2 Inhibitors: 2553 matched pairs were analyzed, with a median follow-up of 1.65 years.
GLP-1s vs. DPP-4 Inhibitors: 2564 matched pairs were analyzed, with a median follow-up of 1.7 years.
The results were compelling. GLP-1 use was associated with lower all-cause mortality compared to DPP-4 inhibitor use. Interestingly, no notable difference in mortality was observed when comparing GLP-1s to SGLT2 inhibitors.
This survival benefit with GLP-1s was consistent across various demographics – age, sex, race (specifically non-Hispanic White individuals), obesity status – and several cancer types, including colorectal, lung, and breast cancer.
While previous research suggested the impact of GLP-1 expression on survival might vary depending on the cancer type, this study provides valuable comparative effectiveness data for GLP-1s themselves. 1
Important Considerations & Future Research
While these findings are encouraging,it’s crucial to acknowledge the study’s limitations. Potential confounding factors and underpowered subgroup analyses highlight the need for further investigation.
This research underscores the importance of well-designed clinical trials to definitively establish the role of GLP-1s in cancer survivorship.
Currently,GLP-1s are not a standard part of cancer treatment. However, the emerging evidence suggests they warrant further exploration as a potential adjunct therapy, particularly for individuals with both T2D and cancer.
If you are managing both diabetes and cancer, discuss these findings with your oncologist and endocrinologist. They can help you determine if GLP-1s, or other diabetes management strategies, are appropriate for your individual situation.
REFERENCES:
- Radwan RM, Lu Y, Dai H, et al.GLP-1 RA Use and Survival Among Older